Sponsored By:

Chart Predicts Top Biotech Is About to Break Out

It appears to be only a matter of time before GILD breaks to new highs

   

Gilead Sciences (GILD) — This has been a favorite biotech stock of mine since Nov. 19, 2012, when I recommended it near $37.50. On Aug. 29, at just over $60, I reiterated my positive opinion, citing an increase in earnings estimates by S&P.

On Nov. 20, Citigroup (C) reiterated its “buy” rating on GILD, increasing its earnings estimate for fiscal 2014 by a nickel to $3.46, and upping its price target to $87 from $85.

In December, S&P repeated its “strong buy” rating and $94 price target following a sell-off it attributed to an unconfirmed Bloomberg report that Express Scripts (ESRX) raised concerns over the price of Gilead’s recently approved hepatitis C drug, Sovaldi. Recently, S&P raised its earnings expectations to $1.89 per share for 2013 and $3.10 for 2014. It also raised its 12-month target price to $104.

Technically, GILD is still in a powerful bull channel with support at its 50-day moving average at $72. Resistance at $76 has been stubborn, but buying volume is eating into the overhead, and it is only a matter of time before GILD breaks to new highs. MACD is moving up from the bearish zone, predicting that a breakout is forthcoming.

Buy GILD at the market for a trade to $85. My 12-month target is $100.

01 15 14 gild 300x191 Chart Predicts Top Biotech Is About to Break Out
Click to Enlarge

chart key 300x84 Chart Predicts Top Biotech Is About to Break Out


Article printed from InvestorPlace Media, http://investorplace.com/2014/01/trade-day-gilead-sciences-gild-4/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.